Human metabolism of tolfenamic acid. I. Isolation, preliminary characterization and pharmacokinetics of tolfenamic acid and its metabolites.

Suppr

超能文献

作者信息

Pentikäinen P J, Penttilä A, Neuvonen P J, Khalifah R G, Hignite C E

出版信息

Eur J Drug Metab Pharmacokinet. 1982 Oct-Dec;7(4):259-67. doi: 10.1007/BF03189628.

DOI:10.1007/BF03189628

PMID:7166178

Abstract

摘要

相似文献

Human metabolism of tolfenamic acid. I. Isolation, preliminary characterization and pharmacokinetics of tolfenamic acid and its metabolites.

Eur J Drug Metab Pharmacokinet. 1982 Oct-Dec;7(4):259-67. doi: 10.1007/BF03189628.

Human metabolism of tolfenamic acid. II. Structure of metabolites and C-13 NMR assignments of fenamates.托芬那酸的人体代谢。II. 代谢物结构及芬那酸盐的碳-13核磁共振归属

Eur J Drug Metab Pharmacokinet. 1982 Oct-Dec;7(4):269-76. doi: 10.1007/BF03189629.

Pharmacokinetics of tolfenamic acid: disposition in bile, blood and urine after intravenous administration to man.托芬那酸的药代动力学：静脉注射给人后在胆汁、血液和尿液中的处置情况。

Eur J Clin Pharmacol. 1984;27(3):349-54. doi: 10.1007/BF00542174.

Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent.新型抗炎药托芬那酸的人体药代动力学

Eur J Clin Pharmacol. 1981;19(5):359-65. doi: 10.1007/BF00544587.

Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.托芬那酸在体外是一种强效的CYP1A2抑制剂，但在体内并无相互作用：数据解读时需要校正蛋白结合率。

Eur J Clin Pharmacol. 2007 Sep;63(9):829-36. doi: 10.1007/s00228-007-0335-z. Epub 2007 Jul 6.

Pharmacokinetics of tolfenamic acid in patients with cirrhosis of the liver.

Eur J Clin Pharmacol. 1985;28(5):573-9. doi: 10.1007/BF00544069.

Pharmacokinetics of tolfenamic acid and its detection time in urine after intravenous administration of the drug in camels (Camelus dromedarius).

Am J Vet Res. 1998 Nov;59(11):1451-8.

Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease.

Eur J Clin Pharmacol. 1986;30(5):591-6. doi: 10.1007/BF00542420.

Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs.工程化细胞色素P450突变体作为生物催化剂用于合成非甾体抗炎药芬那酸的苄基和芳香族代谢产物的应用。

Bioorg Med Chem. 2014 Oct 15;22(20):5613-20. doi: 10.1016/j.bmc.2014.06.022. Epub 2014 Jun 19.

Pharmacokinetics of tolfenamic acid in pediatric patients after single oral dose.

Eur J Drug Metab Pharmacokinet. 1995 Oct-Dec;20(4):293-6. doi: 10.1007/BF03190247.

引用本文的文献

Biocompatible Cationic Lipoamino Acids as Counterions for Oral Administration of API-Ionic Liquids.作为 API-离子液体口服给药的抗衡离子的生物相容的阳离子脂氨基羧酸。

Pharm Res. 2022 Oct;39(10):2405-2419. doi: 10.1007/s11095-022-03305-y. Epub 2022 Jun 3.

Pharmacokinetics of tolfenamic acid in pediatric patients after single oral dose.

Eur J Drug Metab Pharmacokinet. 1995 Oct-Dec;20(4):293-6. doi: 10.1007/BF03190247.

Eur J Clin Pharmacol. 1984;27(3):349-54. doi: 10.1007/BF00542174.

Pharmacokinetics of tolfenamic acid in patients with cirrhosis of the liver.

Eur J Clin Pharmacol. 1985;28(5):573-9. doi: 10.1007/BF00544069.

Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease.

Eur J Clin Pharmacol. 1986;30(5):591-6. doi: 10.1007/BF00542420.

本文引用的文献

Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent.新型抗炎药托芬那酸的人体药代动力学

Eur J Clin Pharmacol. 1981;19(5):359-65. doi: 10.1007/BF00544587.

Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.血浆蛋白药物结合的年龄差异：对人类胎儿、新生儿和成年人的研究。

Eur J Clin Pharmacol. 1971 Sep;3(4):189-93. doi: 10.1007/BF00565004.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验